Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2014; 112(04): 834-836
DOI: 10.1160/TH14-02-0138
DOI: 10.1160/TH14-02-0138
Letters to the Editor
Massive human rivaroxaban overdose
Authors
Further Information
Publication History
Received:
14 February 2014
Accepted after minor revision:
30 April 2014
Publication Date:
20 November 2017 (online)
-
References
- 1 Patel MR, Mahaffey KW, Garg J. et al. ROCKETAF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
- 2 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
- 3 Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
- 4 Eisenberg PR, Siegel JE, Abendschein DR. et al. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883.
- 5 Perzborn E, Strassburger J, Wilmen A. et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
- 6 Bayer Pharma AG. Xarelto (rivaroxaban) summary of product characteristics. 2013.
- 7 Kubitza D, Becka M, Voith B. et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
- 8 Mueck W, Becka M, Kubitza D. et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban- an oral, direct factor Xa inhibitor- in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-344.
- 9 Asmis LM, Alberio L, Angelillo-Scherrer A. et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498.
- 10 Samama MM, Martinoli JL, LeFlem L. Assessment of laboratory assays to measure rivaroxaban- an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
- 11 Barrett YC, Wang Z, Frost C. et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
- 12 Mueck W, Eriksson BI, Bauer KA. et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban- an oral, direct Factor Xa inhibitor- in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
- 13 Eerenberg SE, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban an dabigatran by prothrombin complex concentrate: A randomized placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
- 14 Zhou W, Zorn M, Nawroth P. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke 2013; 44: 771-778.
- 15 Dowlatshahi D, Butcher KS, Asdaghi N. et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 1012; 43: 1812-1817.
- 16 Chyka PA, Seger D, Krenzelok EP. et al. Single-dose activated charcoal. Clin Toxicol 2005; 43: 61-87.